Valbenazine is a
purified isomer of tetrabenazine drug, used to treat tardive
dyskinesia which is a nervous system disorder. Dyskinesia refers to
involuntary muscle movement that can range from slight tremor to
uncontrollable movement of the entire body. Grimacing, tongue
movements, lip smacking, lip puckering, pursing of the lips, etc. are
the common effects of tardive dyskinesia. Valbenazine drug acts as a
vesicular monoamine transporter 2 inhibitor, which is essentially an
integral membrane protein, and decreases the level of dopamine in the
body.
Valbenazine
decreases the level of monoamine neurotransmitters by preventing
their storage in synaptic vesicles. The effect of this drug has been
studied on pregnant women. Subsequently, it is not recommended to
pregnant or breastfeeding women. The symptoms of tardive dyskinesia
can be severe and are often persistent and irreversible. Both
valbenazine and its active metabolite [+]-α-HTBZ have a half-life
period of 15-22 hours and Tmax of 0.5 to 1 hr.
Report Overview @
https://www.transparencymarketresearch.com/valbenazine-market.html
Based on class, the
valbenazine market can be classified into therapeutic (central
nervous system agent), pharmacologic (monoamine depletor), and
chemical (benzoquinolizine). Demand for therapeutic valbenazine is on
the rise, as its effects on the central nervous system help to cure
the disease faster than the other drugs. In terms of end-user, the
valbenazine market can be segmented into hospitals, clinical research
centers, and academic research organizations.
The hospitals
segment is expanding rapidly, as these settings are preferred by
patients for the treatment of tardive dyskinesia disease or other
brain cell disorders. Consumption of alcohol, mental stress, and
prolonged usage of neuroleptic drugs are the major factors driving
the valbenazine market. However, side effects associated with
anticonvulsants and stringent regulations on their usage are some of
the factors anticipated to hamper the growth of the market.
Download Report
Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32486
North America leads
the global valbenazine market because of increasing use of
antipsychotic drugs among adults and children in the U.S. This has
resulted in the rise in prevalence of tardive dyskinesia. According
to the American Academy of Neurology, the newly diagnosed tardive
dyskinesia disease incidence was 26,000, and the incidence rate was
10.6 per 100,000 adults in the U.S. in 2016. According to the WHO,
neuropsychiatric disorder is the third leading cause of
disability-adjusted life years (DALYs) in Europe, and almost 15.2% of
the people are affected by it. This creates a demand for drugs such
as valbenazine.
Asia Pacific is
expected to be the fastest growing market for valbenazine drugs, due
to increase in consumption of alcohol, mental stress, and growth in
population in countries such as India and China. Prevalence of the
disease varies according to ethnic ancestry - people with Asian or
African inheritance have a 1 in 1,000,000 risk of getting affected.
Rise in awareness about mental illness and improvement in the economy
are estimated to drive the market for valbenazine drug in Middle East
& Africa.
Pre-Book Full
Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=32486<ype=S
Neurocrine
Biosciences Inc. is the only key player in the valbenazine drug
market.
About Us
Transparency Market
Research (TMR) is a market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our business offerings represent the latest and the most reliable
information indispensable for businesses to sustain a competitive
edge.
Each TMR syndicated
research report covers a different sector - such as pharmaceuticals,
chemicals, energy, food & beverages, semiconductors, med-devices,
consumer goods and technology. These reports provide in-depth
analysis and deep segmentation to possible micro levels. With wider
scope and stratified research methodology, TMR’s syndicated reports
strive to provide clients to serve their overall research
requirement.
US Office Contact
90 State Street,
Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment